The HCPLive Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.
May 1st 2024
FDA approves label update for voclosporin (Lupkynis) in lupus nephritis, reflecting long-term AURORA data and new kidney function monitoring guidance.
Lupus Nephritis Remission with Cyclosporine, Mycophenolate Mofetil, Azathioprine
June 17th 2019Lupus nephritis remained in remission for over 10 years in a group of patients who were treated with cyclosporine A, mycophenolate mofetil or azathioprine, shows a study presented at the European Congress of Rheumatology (EULAR) annual meeting this weekend in Madrid.
Highlights from EULAR 2019: Treatments for Gout, PsA, Rheumatoid Arthritis, More
June 14th 2019EULAR 2019 wraps this weekend in Madrid. In this slideshow, we highlight some of the most noteworthy findings, beginning with a possible new treatment combination for patients who have both gout and kidney disease.
10 Challenges in Treating Lupus
June 13th 2019We have come a long way since the introduction of glucocorticoids for the treatment of systemic lupus erythematosus (SLE). But even with improved treatment and prognosis several challenges remain in the management of SLE. Here, we highlight the 10 most important challenges in treating patients with SLE.
Rituximab for Lupus Passes Maintenance Therapy Trial
June 13th 2019While rituximab has proven to be an effective treatment for rheumatoid arthritis, it has failed to meet its primary endpoints in clinical trials for systemic lupus erythematosus (SLE). But now, an observational study suggests that rituximab could be effective as maintenance therapy in difficult SLE cases.
A Review of Reactive Arthritis
June 12th 2019Reactive arthritis is an inflammatory joint arthritis largely characterized by joint inflammation triggered by infection. To date, no diagnostic or classification criteria have been established, but in 2014, the American College of Rheumatology issued general treatment guidelines. In this article, we highlight a new review article on treatments for reactive arthritis.
Processed Foods Linked to Heart Disease and Heightened Mortality Risk
June 11th 2019A high consumption of ultra-processed foods (i.e. almost any consumable food item, except fresh fruits and vegetables) is associated with an increased risk of cardiovascular disease and mortality, show two studies in BMJ.
Etanercept Trial Supports Use for JIA, ERA and PsA
June 10th 2019Etanercept is a safe, well-tolerated medication for treating pediatric patients with extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, and psoriatic arthritis, according to the results for a new study.
Biosimilars Report: Switching to Etanercept Biosimilar Doesn't Compromise Safety or Efficacy
June 10th 2019A second study published in May on the safety and efficacy of biosimilars, shows that switching rheumatoid arthritis patients from etanercept (Enbrel, Amgen) to its biosimilar etanercept-szzs (Erelzi, Sandoz), does not affect efficacy, safety or immunogenicity of etanercept.